Iridex Corp.
- IRIX ยท Nasdaq
- Electromedical & Electrotherapeutic Apparatus
- Mountain View, CA
- 93 employees
- CIK 0001006045
Updated from SEC filings through
Top things to know
Executives
- Patrick Mercer President and CEO 4, 2026-07-14
- Romeo R. Dizon Chief Financial Officer 4, 2026-09-16
- Romeo Dizon Chief Financial Officer DEF 14A, 2026-04-24
- Bassem BouHabib Senior Vice President of International Sales and Business Development DEF 14A, 2026-04-24
What leadership is saying
“Our second quarter results were highlighted by the continued momentum in our glaucoma business and operating positive cash flows”
Earnings press release (8-K Ex. 99.1), filed August 18, 2026
Iridex Corp is a U.S. public company in electromedical & electrotherapeutic apparatus (SIC 3845), headquartered in Mountain View, CA. It trades as IRIX on Nasdaq. Revenue was $52.7M in the fiscal year ending January 3, 2026, +8.2% from the year before. It reported about 93 employees. Patrick Mercer is President and CEO.
Five-year financials
| Metric | FY2026 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $52.7M 10-K, 2026-04-02 | $48.7M 10-K, 2026-04-02 | $51.9M 10-K, 2025-03-27 | $57.0M 10-K, 2024-03-29 | $53.9M 10-K, 2023-03-09 |
| Operating income | -$2.6M 10-K, 2026-04-02 | -$8.3M 10-K, 2026-04-02 | -$10.0M 10-K, 2025-03-27 | -$7.5M 10-K, 2024-03-29 | -$7.5M 10-K, 2023-03-09 |
| SG&A | $18.1M 10-K, 2026-04-02 | $22.4M 10-K, 2026-04-02 | $25.0M 10-K, 2025-03-27 | $25.7M 10-K, 2024-03-29 | $23.5M 10-K, 2023-03-09 |
| Net income | -$4.4M 10-K, 2026-04-02 | -$8.9M 10-K, 2026-04-02 | -$9.6M 10-K, 2025-03-27 | -$7.5M 10-K, 2024-03-29 | -$5.2M 10-K, 2023-03-09 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Patrick Mercer Seasoned Executive with a proven track record in Medical Device and Operational Excellence | President and CEO | 4, 2026-07-14 |
| Romeo R. Dizon | Chief Financial Officer | 4, 2026-09-16 |
| Romeo Dizon | Named in proxy bio: Chief Financial Officer | DEF 14A, 2026-04-24 |
| Bassem BouHabib | Named in proxy bio: Senior Vice President of International Sales and Business Development | DEF 14A, 2026-04-24 |
| Scott Shuda | Chairperson of the Board | 10-K, 2026-04-02 |
| Beverly A. Huss | Director | 10-K, 2026-04-02 |
| Nick Chen | Director | 10-K, 2026-04-02 |
| William Moore | Director | 10-K, 2026-04-02 |
Shares and governance
| Shares outstanding | 17.6 million (as of August 13, 2026) | 10-Q, August 18, 2026 |
|---|---|---|
| Public float | $14.2M (as of June 27, 2025) | 10-K, April 2, 2026 |
| Latest proxy statement | Meeting June 12, 2026 (filed April 24, 2026) | DEF 14A, April 24, 2026 |
| Auditor | Bpm LLP (San Jose, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 16, 2026 | Romeo R. Dizon Chief Financial Officer | Buy | 7,900 | $5K | Form 4, September 16, 2026 |
| September 14, 2026 | Romeo R. Dizon Chief Financial Officer | Buy | 2,354 | $2K | Form 4, September 14, 2026 |
| September 10, 2026 | Romeo R. Dizon Chief Financial Officer | Buy | 5,100 | $3K | Form 4, September 10, 2026 |
| August 24, 2026 | Romeo R. Dizon Chief Financial Officer | Buy | 6,668 | $5K | Form 4, August 24, 2026 |
| June 12, 2026 | Romeo R. Dizon Chief Financial Officer | Buy | 975 | $1K | Form 4, June 15, 2026 |
| June 11, 2026 | Romeo R. Dizon Chief Financial Officer | Buy | 1,675 | $2K | Form 4, June 12, 2026 |
| June 8, 2026 | Romeo R. Dizon Chief Financial Officer | Buy | 2,400 | $3K | Form 4, June 9, 2026 |
| June 5, 2026 | Romeo R. Dizon Chief Financial Officer | Buy | 2,521 | $3K | Form 4, June 8, 2026 |
Recent 8-K events
- 8-K filed 2026-09-02
- Item 3.01 Notice of delisting or failure to meet listing standards
- 8-K filed 2026-08-18
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-16
- Item 5.07 Submission of matters to a vote of security holders
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-18
- Item 8.01 Other events
- 8-K filed 2026-05-19
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-13
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-01-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-11
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Iridex Corp
- What does Iridex Corp do?
- Iridex Corp is classified by the SEC as Electromedical & Electrotherapeutic Apparatus (SIC 3845). It is based in Mountain View, CA.
- What is Iridex Corp's revenue?
- $52.7M for the fiscal year ending January 3, 2026, from its 10-K filed April 2, 2026.
- Is Iridex Corp profitable?
- Iridex Corp reported net income of -$4.4M for the fiscal year ending January 3, 2026.
- How many employees does Iridex Corp have?
- About 93 as of January 3, 2026, as stated in its annual report.
- Who is the CEO of Iridex Corp?
- Patrick Mercer, President and CEO, as named in a 4 filed July 14, 2026.
- Who is the CFO of Iridex Corp?
- Romeo R. Dizon, Chief Financial Officer, as named in a 4 filed September 16, 2026.
- Where is Iridex Corp headquartered?
- Mountain View, CA.
- What is Iridex Corp's stock ticker?
- IRIX on Nasdaq.
- What industry is Iridex Corp in?
- Electromedical & Electrotherapeutic Apparatus, SIC code 3845.
- What is Iridex Corp's website?
- iridex.com.
- When does Iridex Corp report earnings next?
- November 17, 2026 at 16:30. Source: ir_events.
- Is Iridex Corp a public company?
- Yes. Iridex Corp files with the SEC under CIK 0001006045 and trades as IRIX.
- Who audits Iridex Corp?
- Bpm LLP, San Jose, California, as named in its latest annual report (10-K).
- How many shares of Iridex Corp are outstanding?
- 17.6 million shares as of August 13, 2026, from its 10-Q filed August 18, 2026.
- What is Iridex Corp's public float?
- $14.2M as of June 27, 2025, as reported on the cover of its 10-K filed April 2, 2026.
- When is Iridex Corp's annual shareholder meeting?
- June 12, 2026, per its proxy statement (DEF 14A) filed April 24, 2026.
- Have Iridex Corp insiders traded stock recently?
- Since August 15, 2025, officers and directors reported 0 open-market sales and 54 purchases worth about $196K on Forms 4 and 5. The most recent: Romeo R. Dizon (Chief Financial Officer) bought 7,900 shares on September 16, 2026.